Background
With early diagnosis, colorectal cancer (CRC) is a curable disease. As studies in the past 15 years have shown, specific genetic changes occur in the neoplastic transformation of normal colonic epithelium to benign adenoma until becoming adenocarcinoma. Considering that dynamic, we aimed to determine how v-raf murine sarcoma viral oncogene homolog B1
(BRAF) V600E
and Kirsten rat sarcoma
(KRAS)
mutations relate to the location, histopathology, and degree of tumor differentiation in CRC.
Methods
With a cross-sectional design involving an observational analytical approach, we determined the relationship of
BRAF V600E
and
KRAS
mutations to the location, histopathology, and degree of tumor differentiation in CRC.
Result
The sample contained 43 patients with CRC aged 21–80 years, with an average age of 56.0 ± 11.2 years, 46.5% of whom were male and 53.5% female, for a male-to-female ratio of 1.0–1.15. Most tumors were located in the right colon (
n
= 18, 41.9%), followed by the rectum (
n
= 14, 32.6%) and left colon (
n
= 18, 25.6%). Non-mucinous adenocarcinoma was more prevalent than mucinous adenocarcinoma, with 22 (51.2%) and 21 (48.8%) patients, respectively. Nineteen tumors were poorly differentiated (44.2%), 15 were moderately differentiated (34.9%), and nine were well-differentiated (20.9%).
BRAF V600E
mutations totaled six (14%), whereas non-
BRAF V600E
mutations totaled 37 (86.0%).
BRAF V600E
mutations significantly related to tumor location, degree of differentiation, and histopathology (
p <
.01).
Conclusion
A significant relationship exists between
BRAF V600E
mutations in the stool of patients with CRC and location, histopathology, and degree of tumor differentiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.